Patent SG-11201805385Q-A (SG)
Title: Bromodomain and extra-terminal protein inhibitor combination therapy
Inventor: NIKOLOVA ZARIANA
IPC: G01N33/574
Filed: 2016-12-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 June 2017 (29.06.2017) WIPOIPCT (10) International Publication Number WO 2017/112703 A1 (51) International Patent Classification: A61P 35/00 (2006.01) A ft IK 9/00 (2006.01) A61K 31/337 (2006.01) G01N 33/574 (2006.01) (21) International Application Number: PCT/US2016/067860 (22) International Filing Date: 20 December 2016 (20.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/387,359 24 December 2015 (24.12.2015) US 62/413,763 27 October 2016 (27.10.2016) US (71) Applicant: CELGENE QUANTICEL RESEARCH, INC. [US/US]; 9393 Towne Centre Drive, Suite 110, San Diego, California 92121 (US). (72) Inventors: NIKOLOVA, Zariana; c/o Celgene Interna­ tional Sari, Route de Perreaux 1, 2017 Boudry (CH). CHO, Robert; 1585 Riorden Terrace, Sunnyvale, Califor­ nia 94087 (US). STAFFORD, Jeffrey Alan; 12752 Sandy Crest Court, San Diego, California 92130 (US). (74) Agents: SUNG, Lawrence M. et al.; Wiley Rein LLP, Pat­ ent Administration, 1776 K Street, NW, Washington, Dis­ trict of Columbia 20006 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY FIG. 8 o i> CJ 2500 ro £ 200 | 1500 :> £ IOOO c S 500 0 10 15 Days of Treatment 20 o CJ (57) : The present disclosure relates generally to compositions and methods of treating cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising the administra­ tion of a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination therapy can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared to the administration of either the BET inhibitor or the chemotherapeutic agent alone.